InvestorsHub Logo
Followers 85
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: Protector post# 228605

Saturday, 11/12/2016 12:24:32 PM

Saturday, November 12, 2016 12:24:32 PM

Post# of 346191

GILD has the profile to be such a potential company for PPHM.
100$ per share + 3 GILD shares? approx 100$+3x120$=460$ ?

That is about 40% of GILDs outstanding shares and equally dared as their previous acquisition. But they get the BIGGEST POTENTIAL EVER in return.
And what GILD needs is POTENTIAL that they can LEVERAGE, not pay for regular income where growth depends only on sales & marketing. With Bavi there is a complete platform to drive growth.

I am SURE GILD would make money on that in less then 5 years.
And GILD would never do the bleed that they would do in cash for a BYM or so.



I wonder where Gilead is today... with all the competition racing to the finish line on I/O combos for the 2nd wave of FDA approvals

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News